Indore Online Journal

Clostridium Difficile Infection (CDI) Market

Clostridium Difficile Infection (CDI) Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

DelveInsight’s “Clostridium Difficile Infections Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Clostridium Difficile Infections, historical and forecasted epidemiology as well as the Clostridium Difficile Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Clostridium Difficile Infections market report provides current treatment practices, emerging drugs, Clostridium Difficile Infections market share of the individual therapies, and current and forecasted Clostridium Difficile Infections market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Clostridium Difficile Infections treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the Clostridium Difficile Infections market.

Some of the key facts of theClostridium Difficile Infection (CDI) Market Report:

• According to Pires et al. (2014), very little is known about the epidemiology of CDI in Latin American countries, and the incidence of CDI may be underestimated in these areas. A total of 96 patients were studied over 12 months (2011–2012). Of these, 60 were men (62.5%), with a median age of 63 years old (range, 19–94). The frequency of CDI in this cohort was 8.3% (8/96). The median age of patients with CDI was 62 years old (range, 19–87), and the majority were male (n = 7, 87.5%). In the CDI group, four patients (50.0%) were solid organ transplant recipients, and 75.0% had undergone liver transplantation. Only one patient (12.5%) had community-acquired CDI. 
• In a study realized by Marcon et al. (2006), 98 stool samples from patients with a mean age of 54 years were analyzed, including 49 controls and 49 cases of diarrhea who were hospitalized for more than 72 h in the intensive care unit (ICU) in a public hospital in Santo Andre. By fecal culture, CDI was identified in 44.9% of all samples tested.

Key benefits of the Clostridium Difficile Infection (CDI) Market report:

• The report covers the descriptive overview of Clostridium Difficile Infections, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Clostridium Difficile Infections epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Clostridium Difficile Infections is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Clostridium Difficile Infections market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Clostridium Difficile Infections market

Got queries? Click here to know more about the Clostridium Difficile Infection (CDI) Market Landscape 

Clostridium Difficile Infection (CDI) Overview

Clostridium Difficile is a gram-positive, anaerobic, spore-forming bacillus that was first identified in 1978 as the predominant bacterial cause of antibiotic-associated diarrhea and pseudomembranous colitis (PMC). In the past 10–15 years, C. difficile infection (CDI) has emerged as an increasingly important infectious disease worldwide. Clostridioides difficile is considered one of the main etiological agents of bacterial diarrhea associated with the use of antibiotics. It is an important nosocomial pathogen and the main cause of morbidity and mortality. 

Some people carry C. difficile bacteria in their intestines but never become sick. These individuals are carriers of the bacteria and may spread infections. Signs and symptoms usually develop within 5–10 days after starting an antibiotic course; however, they may occur as soon as the first day or 3 months later. Clinical manifestations of CDI range from mild diarrhea to life-threatening illnesses. Prediction rules have been developed to predict recurrences, complications, and mortality.

Clostridium Difficile Infection (CDI) Epidemiological Insight:

• In a study realized by Marcon et al. (2006), 98 stool samples from patients with a mean age of 54 years were analyzed, including 49 controls and 49 cases of diarrhea who were hospitalized for more than 72 h in the intensive care unit (ICU) in a public hospital in Santo Andre. By fecal culture, CDI was identified in 44.9% of all samples tested.
• Ferreira et al. (2003) analyzed 181 stools of children (0–5 years) from three public hospitals, of which 90 had acute diarrhea, and 91 were healthy children. The presence of CDI in children with acute diarrhea was 5.5% (10/181). In addition, this work demonstrated that CDI is probably associated with cases of acute diarrhea in Brazil. 
• As per Lopardo et al. (2014),outof included patients, 55% were male, and 45% were female.

Clostridium Difficile Infection (CDI) Epidemiological Segmentation

• Clostridium difficile infection incidence rate
• Clostridium difficile infection gender-specific incidence rate
• Clostridium difficile infection type-specific incidence rate
• Clostridium difficile infection age-specific incidence rate
• Clostridium difficile infection (CDI) type-specific incidence rate
• Clostridium difficile infection recurrent and treatable cases

Clostridium Difficile Infection (CDI) Market Outlook 

The Clostridium Difficile Infections market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Clostridium Difficile Infections market trends by analyzing the impact of current Clostridium Difficile Infections therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Clostridium Difficile Infections market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Clostridium Difficile Infections market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, the Clostridium Difficile Infections market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @Clostridium Difficile Infection (CDI) Market Landscape

Clostridium Difficile Infection (CDI)  Key Companies  

•  Summit Therapeutics
•  Merck Sharp & Dohme LLC 
• and  many others

Clostridium Difficile Infection (CDI)  Therapies 

•  Ridinilazole
• Bezlotoxumab 
• and many others

Table of Contents

• Key Insights 
• Report Introduction 
• Executive Summary of Clostridium Difficile Infection (CDI) 
• Disease Background and Overview
• Epidemiology and patient population
• The United States 
• EU 5
• Clostridium Difficile Infection (CDI)  Emerging Therapies
• Clostridium Difficile Infection (CDI)  Market Outlook
•  Market Access and Reimbursement of Therapies
•  Appendix
• Clostridium Difficile Infection (CDI) Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Click here to read more about Clostridium Difficile Infection (CDI) Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/